Taysha Gene Therapies Inc (NASDAQ:TSHA) shares, rose in value on Thursday, March 27, with the stock price up by 4.44% to the previous day’s close as strong demand from buyers drove the stock to $1.88.
Actively observing the price movement in the last trading, the stock closed the session at $1.80, falling within a range of $1.78 and $1.95. The value of beta (5-year monthly) was 0.885. Referring to stock’s 52-week performance, its high was $4.32, and the low was $1.19. On the whole, TSHA has fluctuated by 16.05% over the past month.
With the market capitalization of Taysha Gene Therapies Inc currently standing at about $385.40 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Feb-25.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 1.48M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that TSHA’s technical picture suggests that short-term indicators denote the stock is a Hold on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a 50% Sell.
The stock’s technical analysis shows that the price of TSHA currently trading nearly 9.21% and 14.13% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 61.85, while the 7-day volatility ratio is showing 8.44% which for the 30-day chart, stands at 6.75%. Furthermore, Taysha Gene Therapies Inc (TSHA)’s beta value is 0.82, and its average true range (ATR) is 0.13.
A comparison of Taysha Gene Therapies Inc (TSHA) with its peers suggests the former has fared considerably weaker in the market. TSHA showed an intraday change of 4.44% in last session, and over the past year, it shrunk by -38.56%%.
Data on historical trading for Taysha Gene Therapies Inc (NASDAQ:TSHA) indicates that the trading volumes over the past 10 days have averaged 2.02 and over the past 3 months, they’ve averaged 1.95 million. According to company’s latest data on outstanding shares, there are 204.94 million shares outstanding.
Nearly 19.51% of Taysha Gene Therapies Inc’s shares belong to company insiders and institutional investors own 77.27% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 25.25 million shares as on 2025-03-14, resulting in a short ratio of 15.72. According to the data, the short interest in Taysha Gene Therapies Inc (TSHA) stood at 1625.00 of shares outstanding as of 2025-03-14; the number of short shares registered in 2025-02-14 reached 25.09 million. The stock has risen by 8.67% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the TSHA stock heading into the next quarter.
